arrow
M

Michele Bartoletti

istituto nazionale tumori irccs fondazione “g
H指数:22
被引数:1,399
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

KELIM score: A marker of chemosensitivity in ovarian cancer

KELIM评分:卵巢癌化疗敏感性的标志物

2025-12-180
PRE
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study

头孢地尔ocol在治疗革兰氏阴性菌感染中的实际应用:单药治疗或联合治疗——多中心回顾性CEFI-BAC研究

2025-12-060
OAAI
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer

曲妥珠单抗德鲁替康(T-DXd)在HER2阳性转移性子宫内膜癌中的显著疗效

2025-10-240
OAAI
How to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: the role of [18F]-FDG-PET/CT imaging - An international multidisciplinary survey

如何管理接受长期抑菌抗生素治疗的心脏瓣膜感染患者:[18F]-FDG-PET/CT成像的作用——一项国际多学科调查

2025-09-270
OAAI
Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study

奥密克戎时代B细胞恶性肿瘤患者持续性SARS-CoV-2感染的危险因素:一项多中心队列研究

2025-09-080
OAAI
A randomized, phase III study of sacituzumab govitecan versus treatment of physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)

一项关于sacituzumab govitecan与医生选择治疗方案在经过铂类化疗和免疫治疗后的子宫内膜癌患者中的随机、III期研究:ASCENT-GYN-01研究(GOG-3104/ENGOT-en26/APGOT-EN2)。

2025-09-070
PRE
Role of remdesivir for the treatment of COVID-19 in patients with hematologic malignancy—A narrative review and expert opinion

瑞德西韦在血液系统恶性肿瘤患者中治疗COVID-19的作用——一篇叙述性综述和专家意见

2025-08-220
OAAI
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses

高级别浆液性卵巢癌类器官培养物中药物反应的纵向预测与临床反应的一致性

2025-08-070
OAAI
First-line combination therapy with fifth generation cephalosporins plus daptomycin compared to other-antimicrobial-regimens for methicillin-resistant Staphylococcus aureus bacteraemia: a multicenter retrospective cohort study

与其它抗菌药物方案相比,使用第五代头孢菌素联合达托霉素作为一线联合疗法治疗耐甲氧西林金黄色葡萄球菌菌血症的多中心回顾性队列研究

2025-04-240
OA
Controversies in the management of grade 1 and 2 endometrioid carcinoma of the ovary and uterus

卵巢和子宫的1级和2级子宫内膜样癌的管理争议

2025-01-010
PRE
USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity
2024-11-150
OAAI
Author Correction: Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer
2024-07-120
OAAI
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways
2024-07-012
OAAI
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024-07-014
PRE
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

铂诱导的ITGA6上调促进卵巢癌的化学抗性和扩散

2024-04-241
OAAI
Static and microfluidic platforms for novel therapeutic testing in high-grade serous ovarian cancer
2024-04-050
PRE
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

将anti-PD1或抗PD-L1药物掺入基于铂的化疗,用于晚期或复发性子宫内膜癌的初步治疗。一项荟萃分析

2024-04-013
OAAI
Copper nitroprusside: An innovative approach for targeted cancer therapy via ROS modulation
2024-02-014
OAAI
Silver nitroprusside as an efficient chemodynamic therapeutic agent and a peroxynitrite nanogenerator for targeted cancer therapies
2024-02-0115
OAAI